CA2162271A1 - Proteines de fusion renfermant une proteine rep. d'anedovirus et une proteine bacterienne - Google Patents

Proteines de fusion renfermant une proteine rep. d'anedovirus et une proteine bacterienne

Info

Publication number
CA2162271A1
CA2162271A1 CA002162271A CA2162271A CA2162271A1 CA 2162271 A1 CA2162271 A1 CA 2162271A1 CA 002162271 A CA002162271 A CA 002162271A CA 2162271 A CA2162271 A CA 2162271A CA 2162271 A1 CA2162271 A1 CA 2162271A1
Authority
CA
Canada
Prior art keywords
protein
rep
adeno
associated virus
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002162271A
Other languages
English (en)
Inventor
Robert Kotin
Brian Safer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2162271A1 publication Critical patent/CA2162271A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

L'invention concerne une protéine de fusion contenant une protéine rep de virus associé à l'adénovirus, un fragment ou un dérivé de cette dernière, ainsi qu'une protéine ou un peptide autre qu'une protéine ou un peptide de virus associé à l'adénovirus. On produit ladite protéine de fusion à l'aide de techniques de génie génétique dans lesquelles on produit un véhicule d'expression comprenant une première séquence d'ADN codant une protéine rep de virus associé à l'adénovirus, un fragment ou un dérivé de cette dernière, ainsi qu'une deuxième séquence d'ADN codant une protéine ou un peptide autre qu'une protéine de virus associé à l'adénovirus, l'expression desdites première et deuxième séquences d'ADN induisant l'expression d'une protéine de fusion comprenant la protéine rep de virus associé à l'adénovirus, un fragment ou un dérivé de cette dernière, et la protéine ou le peptide tels que la protéine fixant le maltose d'E. coli ne constituant pas une protéine ou un peptide de virus associé à l'adénovirus. Lesdites protéines de fusion peuvent être produites et purifiées en grandes quantités, la partie de la protéine rep de virus associé à l'adénovirus de la protéine de fusion conservant son activité biologique.
CA002162271A 1993-05-26 1994-05-26 Proteines de fusion renfermant une proteine rep. d'anedovirus et une proteine bacterienne Abandoned CA2162271A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6723693A 1993-05-26 1993-05-26
US08/067,236 1993-05-26
PCT/US1994/005940 WO1994028157A1 (fr) 1993-05-26 1994-05-26 Proteines de fusion contenant une proteine rep de virus associe a l'adenovirus et proteine bacterienne

Publications (1)

Publication Number Publication Date
CA2162271A1 true CA2162271A1 (fr) 1994-12-08

Family

ID=22074622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002162271A Abandoned CA2162271A1 (fr) 1993-05-26 1994-05-26 Proteines de fusion renfermant une proteine rep. d'anedovirus et une proteine bacterienne

Country Status (4)

Country Link
EP (1) EP0733122A4 (fr)
JP (1) JPH09501309A (fr)
CA (1) CA2162271A1 (fr)
WO (1) WO1994028157A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342390B1 (en) * 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
DE19545126A1 (de) 1995-12-04 1997-06-05 Hoechst Ag ATP- und Nukleinsäure-bindendes Protein mit Helikase-Eigenschaften
JP2001500376A (ja) * 1996-09-06 2001-01-16 カイロン コーポレイション 組換えａａｖベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
EP1047784B2 (fr) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Antigenes du neisseria meningitidis
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP2975127A1 (fr) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Peptites antigènes de neisseria
EP2275129A3 (fr) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Vaccin omv complèté contre la méningocoque
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2335723A1 (fr) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation contre la Chlamydia trachomatis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CN104292321A (zh) 2004-03-29 2015-01-21 株式会社嘉尔药物 新的半乳凝素9 突变体蛋白质及其用途
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
DE4036784A1 (de) * 1990-11-17 1992-05-21 Behringwerke Ag Antivirale aktivitaet des vom adeno-assoziierten virus typ 2 codierten rep-gens

Also Published As

Publication number Publication date
WO1994028157A1 (fr) 1994-12-08
EP0733122A4 (fr) 1998-06-10
EP0733122A1 (fr) 1996-09-25
JPH09501309A (ja) 1997-02-10

Similar Documents

Publication Publication Date Title
CA2162271A1 (fr) Proteines de fusion renfermant une proteine rep. d'anedovirus et une proteine bacterienne
CA2205874C (fr) Vesicules lipidiques contenant la proteine rep de virus adeno-associe pour integration transgenique et therapie genique
JP2525438B2 (ja) ファクタ―８：ｃの製造方法
WO1996015777A9 (fr) Vesicules lipidiques contenant la proteine rep de virus adeno-associe pour integration transgenique et therapie genique
WO1994028157A9 (fr) Proteines de fusion contenant une proteine rep de virus associe a l'adenovirus et proteine bacterienne
KR0148575B1 (ko) 효소원 또는 피브린 특이성을 갖는 조직 플라스미노겐 활성제
CA2278616C (fr) Adenovirus comprenant des proteines d'hexon modifiees
KR100257457B1 (ko) 인간응집인자 viii 단백질 복합체의 제조방법
JP2003530064A (ja) 遺伝子治療用のコートタンパク質改変バキュロウイルス−ベクター
US20070287660A1 (en) Novel clot-specific steptokinase proteins possessing altered plasminogen activation-characteristics and a process for the preparation of said proteins
JP2001500376A (ja) 組換えａａｖベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
CA2072649C (fr) Materiel et methodes d'expression d'une forme modifiee du plasminogene humain
CA1341459C (fr) Enzymes fibrinolytiques modifiees
WO2022191168A1 (fr) Procédé de production d'un virion de aav9 recombiné
JPH022376A (ja) 酵素前駆体型ヒトプロテインｃの発現のためのベクターおよび化合物
JPS6312299A (ja) ポリペプチドの生産のための発現ベクタ−、ポリペプチドの交換発現法、発現ベクタ−を含有する宿主、それによりつくられた生産物
WO1996040269A1 (fr) Augmentation du titre de vecteurs de virus recombine de type adenovirus
JP2534332B2 (ja) ポリペプチド化合物
CA2297660C (fr) Production de proteines mutantes humaines dans des cellules humaines par recombinaison homologue
JPS62289199A (ja) ヒトプロテインｓ
JPH05508771A (ja) Ａｎｃｒｏｄ類似蛋白質、その製造及び使用
WO1995023861A1 (fr) MEGACARYOPOIETINE HUMAINE ET ISOLEMENT DE CELLE-CI, CLONAGE D'ADNc, ET PREPARATION DE LA PROTEINE RECOMBINEE
JPS63270697A (ja) ヒト腫瘍壊死因子関連蛋白質
JPH04197184A (ja) トロンビン阻害活性を有する新規ポリペプチドおよびその製造法
JPH0453489A (ja) プロウロキナーゼの遺伝子工学的製造法

Legal Events

Date Code Title Description
FZDE Discontinued